PTH: Potential role in management of heart failure.
Biomarkers play an important role for the diagnosis and prognosis of heart failure (HF), a disease with high morbidity and mortality as well as a huge impact on healthcare budgets. Parathyroid hormone (PTH) is a major systemic calcium-regulating hormone and an important regulator of bone and mineral homeostasis. PTH testing is important for differential diagnosis of calcemia related disorders and for the management of patients with chronic kidney disease. As secondary hyperparathyroidism has been evidenced in HF patients, PTH testing might be relevant in HF patients for risk stratification and more personalized selection of treatment.
Pôle de recherche en Endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium; Department of Laboratory Medicine, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium. Electronic address: damien.gruson@uclouvain.be.
D
D
Gruson
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA.
A
A
Buglioni
Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MN, USA.
J C
JC
Burnett
D000818:Animals; D000089703:Fibroblast Growth Factor-23; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D009206:Myocardium / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood / Q000378:metabolism*
C000717427:FGF23 protein, human; D010281:Parathyroid Hormone; D000089703:Fibroblast Growth Factor-23
Aldosterone; BNP; FGF-23; Heart failure; Multimarker; Parathyroid hormone